CASP3 and breast carcinoma: (113) mentioned that Fumigaclavine C could significantly downregulate the expression of NF-κB, inhibit the MAPK signaling pathway and induce caspases-3, -8 and -9-mediated apoptosis to inhibit breast cancer development, thus it may be used as a targeted therapy for breast cancer.